AD)

Award Number: DAMD17-00-1-0010

TITLE: The Function of PTEN Tumor Suppressor Gene in Prostate

Cancer Development

PRINCIPAL INVESTIGATOR: Hong Wu, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of California, Los Angeles

Los Angeles, California 90095-1735

REPORT DATE: March 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	DATES COVERE	D
	March 2001	Annual (15 Feb	00 − 14 Fe	eb 01)
4. TITLE AND SUBTITLE			5. FUNDING N	UMBERS
The Function of PTEN Tum	or Suppressor Gene in	Prostate	DAMD17-00-	1-0010
Cancer Development				
_				
6. AUTHOR(S)				
Hong Wu, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAM	• • •		8. PERFORMING	G ORGANIZATION
Universtiv of California. Los Angel Los Angeles, California 90095-173			REPORT NO	WIDEN
Los Angeles, Camornia 90093-173	,,			
E-Mail: hwu@mednet.ucla.edu				
E-Iviaii: nwu(a)meunet.ueta.edu				
9. SPONSORING / MONITORING AGE	NOV NAME(C) AND ADDRESSIES	1	10 SPONSORII	NG / MONITORING
9. SPONSORING / MONITORING AGE	NCT NAME(S) AND ADDRESS(ES	''	AGENCY REPORT NUMBER	
U.S. Army Medical Research and M	Nateriel Command		***************************************	
Fort Detrick, Maryland 21702-5012				
Fort Detrick, Wai yland 21702-3012	2			
11. SUPPLEMENTARY NOTES				
This report contains col	ored photos			
lines report comparing con-	.020a p			
12a. DISTRIBUTION / AVAILABILITY S			12b. DISTRIBUTION CODE	
Approved for Public Rele				
				,
13. ABSTRACT (Maximum 200 Words	5)			

Prostate cancer is the most common malignancy in men. Studying the biology of prostate cancer and development of new therapies are hampered by a lack of insight into the molecular basis of the disease and appropriate animals models. The recently identified tumor suppressor gene PTEN is a promising candidate for being involved in prostate cancer since it is frequently deleted in prostate cancer, especially in advanced or metastatic forms.

To study the function of PTEN in prostate cancer development, we have deleted Pten gene and generated an animal model system. Mice lacking one allele of Pten gene developed prostate abnormalities, ranging from hyperplasia to malignant carcinomas, starting from the 8th month. To accelerate this process, we have generated Pten^{loxp/loxp} mice, which will allow us to delete Pten specifically in the prostate glands. We are currently breeding the Pten^{loxp/loxp} mice with prostate specific Cre transgenic mice. We have also generated a TAT-Cre fusion protein which will allow us to focally delete Pten by surgical injection into the prostate. This study will not only allow us to better understand the function of PTEN in prostate cancer, but will generate a novel animal model for possible treatment.

14. SUBJECT TERMS prostate cancer, PTEN	tumor suppressor, anima	al model	15. NUMBER OF PAGES 13 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover	1
SF 298	2
Introduction	4
Body	5-7
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusions	8
References	9
Appendices	10

INTRODUCTION

PTEN is a tumor suppressor gene frequently deleted in many human cancers, including prostate cancers. The goal of this funded proposal is to study the function of PTEN in prostate cancer development in vivo. Since loss of PTEN function causes embryonic lethality, we proposed to specifically inactive Pten in the prostate.

Three specific tasks should be accomplished in this study:

- I. To characterize Pten^{loxp/loxp} mouse strain;
- II. To inactive Pten in the secretory epithelium of the prostate gland by intercrossing Pten^{loxp/loxp} and probasin Cre transgenic mice;
- III. To forcally inactive Pten through injection of CMV-Cre-T adenovirus into the prostate of Pten loxp/loxp mice.

BODY: STUDIES AND RESULTS

- I. To characterize Ptenloxp/loxp mouse strain
- I-1. To generate Pten^{loxp/loxp} mouse strain on 129svJ/C57Bl/6 and 129svJ/Balb/c backgrounds

Achieved.

I-2. To generate isogenic 129svJ Pten^{loxp/loxp} mouse strain

One important consideration in generating mouse models for genetic diseases in their genetic background. Since possible influence of genetic background on prostate cancer have not been previously reported, we initially proposed to generate isogenic 129svJ mouse strain for future backcrossing to other genetic background.




Figure 1. $Pten^{+/-}$ mice develop prostate cancer.

Seventy-five percent *Pten*^{+/-} mice at age of 9-15 months developed prostate abnormalities, ranging from hyperplasia to hyper-proliferative carcinoma.

- A. Prostate glands from WT (upper) and *Pten*^{+/-} (lower) animals, showing prostate cancer in the ventral and anterior lobes.
- B. H & E staining of prostate section from WT animal (100x).
- C. H & E staining of prostate section (ventral lobe, 100x) from *Pten*^{+/-} animal.

During the past year, we have conducted detailed study on Pten^{+/-} mice, especially the possible impacts of different genetic backgrounds on prostate cancer development. As reported by others (Di Cristofano et al., 1998; Podsypanina et al., 1999; Stambolic et al., 1998; Suzuki et al., 1998), Pten+/-mice under 129/C57Bl/6 develop tumors in multiple organs at early stage of adulthood (3-4 months). However, only hyperplastic changes were observed in the prostate glands of the mutant mice (Di Cristofano et al., 1998). In contrast, mice under 129/Balb/c background had rather late onset of tumor development (Lesche and Wu, unpublished results). Pten^{+/-} mice under such genetic background were free of tumor for the first 6 months of their life. Interestingly, 75-85% of males developed prostate abnormalities, ranging from hyperproliferation to malignant carcinomas, starting from the 8th month (see Figure 1). The molecular mechanisms of such genetic background influence are very important and currently under investigation. On the other hand, these data suggest that establishment and maintaining the 129svJ Pten^{loxp/loxp} mouse strain is no longer necessary.

I-3. To characterize Pten^{loxp/loxp} mouse strain

As a prerequisite for subsequent inactivation, it is crucial to prove that introduction of loxp sites into the introns on either side of exon 5 has not effects on the function of PTEN in Pten^{loxp/loxp} mice. For this, we have followed a cohort of Pten^{loxp/loxp} mice over a period of 1.5 year. In contrast to Pten^{-/-} mice which die at early stage of embryogenesis, Pten^{loxp/loxp} mice showed no signs of abnormalities and free of tumors, suggesting that PTEN function is intact in these mice. Further study also indicated that the amount of PTEN protein produced in the Pten^{loxp/loxp} mice are comparable to the WT mice (data not shown).

II. <u>To inactivate Pten in the prostate secretory epithelium by intercrossing Pten loxp/loxp</u> mice and probasin-Cre transgenic mice.

We have obtained probasin-Cre transgenic mice from Drs. Norm Greenberg and also signed MTA for PB-Cre4 mice (a modified probasin promoter driven Cre recombinase, see appendix) with Dr. Roy-Burman at USC. Animal breeding is in progress with a final goal to obtain Pten^{loxp/loxp}; Cre^{+/-} and Pten^{loxp/d5}; Cre^{+/-} mice.

III. <u>To focally inactivate Pten through injection of CMV-Cre-T sdenovirus into the prostate of Pten^{loxp/loxp} mice.</u>

We have conducted a preliminary experiment by injecting CMV-Cre-T (provided by Dr. Lily Wu, UCLA School of Medicine) directly into the mouse prostates. The injection was successful and we were able to deliver approximately 1 X 10⁹ viral particles into individual prostate gland. Excision of exon 5, which was flanked by the loxp sequences, could be detected in the injected prostate gland (data not shown). However, since the adenovirus vector used here belongs to the first generation of viral vector, significant immune response were observed in the injected mice: including enlarged surrounding lymph nodes and lymphoid cell infiltration. The immune response would complicate the outcome of this experiment. To overcome this problem, two alternative approaches were investigated:

III-1. To generate a "gut-less" adenovirus vector carrying the Cre recombinase

Dr. Lily Wu, our collaborator, is generating such vector now.

III-2. To generate a TAT-Cre fusion protein for protein transduction

Recently, a novel technique has been discovered that might allow one to focally deliver Cre recombinase in vivo. The novel technology co-opts the interesting ability of the HIV TAT protein to cross cell membranes in a receptor-independent and endocytosis-independent manner. Although its mechanism of action is unclear, a 36 amino acid domain of TAT has been defined to mediate this phenomenon (Nagahara, 1998). By fusing this TAT domain to Cre recombinase, we hope to develop a novel molecule that will be able to delete Pten gene in vivo in a temporal and spatial controlled manner. We have generated TAT-Cre fusion protein and proved its function in tissue cultured cells. We have also injected TAT-Cre fusion protein into to ventricle of Pten^{loxp/+} mouse brain and detected exon 5 excision of the flexed-Pten locus (Figure 2). We have now produced enough TAT-Cre proteins and will inject them directly into the prostate glands of Pten^{loxp/lox} mice.




Figure 2. Conditional knock-out of floxed-Pten allele.

- A. *PTEN*-conditioned allele. Exon 5 of the *PTEN* gene is flanked by the loxp sequences. P1 to P3 are PCR primers. When Cre is available, exon 5 will be deleted and create a *Pten* Δ 5 allele.
- B. PCR genotyping. Left four lanes are genotype controls. Lane 5 is uninjected *Pten^{loxed/+}* mouse and lane 6 is *Pten^{loxed/+}* mouse brain injected with TAT-Cre.

KEY RESEARCH ACCOMPLISHMENTS

- Established and characterized Pten conditional knock-out mouse strain: Pten loxp/loxp
- Proved important role of PTEN in prostate cancer development by studying Pten^{+/-} male mice under Balb/c/129 background
- Obtained probasin-Cre transgenic mice for prostate epithelium-specific deletion of Pten
- Generated TAT-Cre fusion protein for focal deletion of Pten gene in the prostate glands

REPORTABLE OUTCOMES

- Publication: Dubey, P., **Wu, H.**, Reiter, R. and Witte, O. (2001) Alternative Pathways to Prostate Carcinoma Activated PSCA Expression, Cancer Research (in press).
- Presentation: CapCure Annual Meeting, Sept. 2000, Lake Tahoe, Nevada
- Repositories: NCI Animal Models for Human Cancers Consortium

CONCLUSION

Our study on Pten knock-out mice suggest that PTEN is a crucial tumor suppressor gene in controlling the prostate cancer development. Thus, prostate-specific deletion of Pten will provide a valuable model for studying prostate cancer, especially signaling pathways involved in prostate cancer formation. Results derived from this study will provide molecular insight to tumorigenesis in the prostate glands and possible therapeutic intervention for treatment of prostate cancers.

REFERENCES

- 1. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression, Nature Genetics *19*, 348-55.
- 2. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., and Parsons, R. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems, Proceedings of the National Academy of Sciences of the United States of America 96, 1563-8.
- 3. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell *95*, 29-39.
- 4. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., *et al.* (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice, Current Biology 8, 1169-78.
- 5. Nagahara, H., Vocero-Akbani, A., Snyder, E.L., Ho, A., Latham, D.G., Lissy, N.A., Becker-Hapak, M., Ezhevsky, S.A., Dowdy, S.F. (1998) Transduction of full length TAT fusion proteins into mammalian cells: p27kip1 mediates cell migration. Nature Medicine 4:1449-1452.

APPENDICES

MTA for PB-Cre4 mice.



January 9, 2001

Office of Technology Licensing

Hong Wu, M.D., Ph.D.

Howard Hughes Medical Institute Research Laboratories

University of California, Los Angeles

Department of Molecular and Medical Pharmacology, Box 951606

Los Angeles, California 90095-1606

Re:

Material Transfer Agreement

Probasin-Cre Mouse Line (Dr. Roy-Burman)

Dear Dr Wu:

Please find enclosed in triplicate the Material Transfer Agreement for the materials you requested from Dr. Roy-Burman. Please sign, as well as, obtain the signatures from an authorized representative and return all three (3) originals to my attention. Upon receipt of the signed originals, I will obtain the final signatures and send a fully executed original for your files.

Thank you for your interest. If you have any questions regarding this matter, please do not hesitate to contact me by telephone at (213) 743-2282 or by e-mail at deaenlle@usc.edu.

Sincerely,

Rhea de AenNe

Enclosure

pc:

Dr. Roy-Burman (w/o enclosures)

RD/sp

University of Southern California 3716 South Hope Street Suite 313 Los Angeles, California 90007-4344 Tel: 213 743 2282 Fax: 213 744 1832 web page: http://www.usc.edu/ academe/otl

MATERIAL TRANSFER AGREEMENT

This Material Transfer Agreement ("MTA") is effective beginning on the date of the latter of two authorized signatures of the parties. The parties in this Agreement are the University of Southern California, the University of Manitoba (hereinafter referred to as "PROVIDERS") and University of California, Los Angeles School of Medicine (hereinafter referred to as "RECIPIENT"). The Research Material, defined below, will be provided by Dr. Pradip-Roy-Burman, Professor, USC Department of Pathology (hereinafter referred to as "PROFESSOR") to the RECIPIENT.

- 1. PROVIDERS agree to transfer to RECIPIENT the following Research Material: Probasin-Cre mouse line (specifically designated as PB-Cre4 mouse line) relating to USC File No. 2994.
- 2. This Research Material will be used by RECIPIENT solely in connection with the following evaluation research project ("Evaluation Project") described with specificity as follows:

RECIPIENT will be using the Research Material to study the function of PTEN tumor suppressor.

- 3. This Research Material will only be used for research purposes by RECIPIENT in their laboratories under suitable containment conditions. This Research Material will not be used for commercial purposes such as screening, production or sale, for which a commercialization license may be required. The Research Material will not be used for in vivo testing in human subjects. RECIPIENT agrees to comply with all Federal rules and regulations applicable to the Evaluation Project and the handling of the Research Material.
- 4. RECIPIENT agrees to treat in confidence, for a period of five (5) years from the date of its disclosure, any of PROVIDERS' written information about this Research Material that is stamped "CONFIDENTIAL." Notwithstanding this provision, RECIPIENT shall not have any obligation under this AGREEMENT with respect to information disclosed by the PROVIDERS to the extent that RECIPIENT can document that the information:
 - a. was in the public domain at the time the PROVIDERS communicated such information to RECIPIENT;
 - b. entered the public domain through no fault of RECIPIENT subsequent to the time the PROVIDERS communicated such information to RECIPIENT;
 - c. was in RECIPIENT's possession free of any obligation of confidence at the time the PROVIDERS communicated such information to RECIPIENT;
 - d. was rightfully communicated to RECIPIENT by a third party free of any obligation of confidence subsequent to the time the PROVIDERS communicated such information to RECIPIENT; or
 - e. was developed by employees or agents of RECIPIENT without reference to any information that the PROVIDERS have disclosed in confidence to any third party.
- 5. This Research Material represents a significant investment of the part of PROVIDERS, and is considered proprietary to the PROVIDERS. RECIPIENT therefore agrees to retain control over this Research Material, and further agrees not to transfer the Research Material to other people not under its direct supervision without advance written approval of the PROVIDERS. The PROVIDERS reserve the right to distribute the Research Material to others and to use it for its own purposes. When the Evaluation Project is completed, the Research Material will be destroyed by RECIPIENT or otherwise disposed of as mutually agreed by provider and RECIPIENT.

- 6. THIS RESEARCH MATERIAL IS BEING SUPPLIED TO RECIPIENT WITH THE UNDERSTANDING THAT IT IS EXPERIMENTAL IN NATURE AND WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR PURPOSE. The PROVIDERS makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.
- 7. RECIPIENT shall bear all risk to itself and/or any others resulting from any use, directly or indirectly, to which it puts the Research Materials or any other material that could not have been made but for these Research Materials.
- 8. RECIPIENT agrees to defend, indemnify, and hold harmless PROVIDERS from any loss, claim, damage, or liability, of any kind whatsoever, which may arise from RECIPIENT'S use, storage or disposal of the MATERIAL, except to the extent arising due to the gross negligence of PROVIDERS.
- 9. RECIPIENT understands that no other right or license to these Research Materials or any other material that could not have been made but for these Research Materials or to their use is granted or implied as a result of PROVIDERS' transmission of these Research Materials to you. Except for use of the Research Materials in the specific Evaluation Project recited above, no license is granted to any intellectual property rights owned by the PROVIDERS.
- 10. The Research Materials are to be used with caution and prudence in any experimental work, since all of their characteristics are not known.
- 11. RECIPIENT will acknowledge the PROFESSOR for providing the Research Materials in the publication or have PROFESSOR and his/her colleagues as co-authors dependent on the nature of the collaboration. The RECIPIENT will update the PROFESSOR on new findings prior to publication.

PROVIDERS	RECIPIENT
UNIVERSITY OF SOUTHERN CALIFORNIA	UNIVERSITY OF CALIFORNIA, LOS ANGELES SCHOOL OF MEDICINE
BY: Dennis F. Dougherty	BY: Jan tucce
TITLE: Senior Vice President, Administration	TITLE: The admin
DATE: /2/13/00	DATE: 1/18/01
DR. PRADIP ROY-BURMAN	HONG WU, M.D., PH.D DEPARTMENT OF MOLECULAR AND MEDICAL PHARMACOLOGY
BY:	BY:
DATE:	DATE: [10 0
UNIVERSITY OF MANYTOBA	
BY:	
Desident (Administration	